|
|||
|
Frau Petra Keikavoussi
|
Research Interests:
Special clinical interests:
Selected References:
1: Hartmann A, Bedenk C, Keikavoussi P, Becker JC, Hamm H, Bröcker EB. Vitiligo and melanoma-associated hypopigmentation (MAH): shared and discriminative features. J Dtsch Dermatol Ges. 2008 Dec;6(12):1053-9. Epub 2008 May 7. English, German. PubMed PMID: 18479500.
2: Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB,
Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev
J, Burg G, Jonuleit H, Tüttenberg A, Becker JC, Keikavoussi P, Kämpgen E, Schuler
G; DC study group of the DeCOG. Dacarbazine (DTIC) versus vaccination with
autologous peptide-pulsed dendritic cells (DC) in first-line treatment of
patients with metastatic melanoma: a randomized phase III trial of the DC study
group of the DeCOG. Ann Oncol. 2006 Apr;17(4):563-70. Epub 2006 Jan 17. PubMed
PMID: 16418308.
3: Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC.
Complete remission of liver metastasis of pancreatic cancer under vaccination
with a HLA-A2 restricted peptide derived from the universal tumor antigen
survivin. Cancer Immunol Immunother. 2006 Oct;55(10):1294-8. Epub 2005 Nov 29.
PubMed PMID: 16315030.
4: Ugurel S, Hildenbrand R, Zimpfer A, La Rosée P, Paschka P, Sucker A,
Keikavoussi P, Becker JC, Rittgen W, Hochhaus A, Schadendorf D. Lack of clinical
efficacy of imatinib in metastatic melanoma. Br J Cancer. 2005 Apr
25;92(8):1398-405. PubMed PMID: 15846297.
5: Otto K, Andersen MH, Eggert A, Keikavoussi P, Pedersen LØ, Rath JC, Böck M,
Bröcker EB, Straten PT, Kämpgen E, Becker JC. Lack of toxicity of therapy-induced
T cell responses against the universal tumour antigen survivin. Vaccine. 2005 Jan
4;23(7):884-9. PubMed PMID: 15603888.
6: Schrama D, Pedersen LØ, Keikavoussi P, Andersen MH, Straten Pt P, Bröcker EB,
Kämpgen E, Becker JC. Aggregation of antigen-specific T cells at the inoculation
site of mature dendritic cells. J Invest Dermatol. 2002 Dec;119(6):1443-8. PubMed
PMID: 12485452.
7: Andersen MH, Keikavoussi P, Bröcker EB, Schuler-Thurner B, Jonassen M,
Søndergaard I, Straten PT, Becker JC, Kämpgen E. Induction of systemic CTL
responses in melanoma patients by dendritic cell vaccination: cessation of CTL
responses is associated with disease progression. Int J Cancer. 2001 Dec
15;94(6):820-4. PubMed PMID: 11745484.
8: Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H,
Röder C, Haendle I, Leisgang W, Dunbar R, Cerundolo V, von Den Driesch P, Knop J,
Bröcker EB, Enk A, Kämpgen E, Schuler G. Mage-3 and influenza-matrix
peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+
melanoma patients by mature monocyte-derived dendritic cells. J Immunol. 2000 Sep
15;165(6):3492-6. PubMed PMID: 10975870.
9: Neumann M, Fries H, Scheicher C, Keikavoussi P, Kolb-Mäurer A, Bröcker E,
Serfling E, Kämpgen E. Differential expression of Rel/NF-kappaB and octamer
factors is a hallmark of the generation and maturation of dendritic cells. Blood.
2000 Jan 1;95(1):277-85. PubMed PMID: 10607713.
